Day One Agenda
Please Note: Times Listed as EST | PST
8:00 am Registration & Virtual Networking
8:25 am Chair’s Opening Remarks
TIGIT Axis Targeted Therapies in Review
8:30 am An Overview of the Current Development, Clinical Trials, & Key Players in the Clinical Trial Landscape of TIGIT Therapies
Synopsis
- Providing a comprehensive analysis of the TIGIT trials and therapies
- Reviewing TIGIT development in the context of the current IO R&D landscape
- Sharing Insights into the rapidly evolving TIGIT pipeline, combination approaches and future trends
9:00 am SWOT Analysis Panel Discussion:
Synopsis
• What happened in the SKYSCRAPER trial?
• Progress, momentum and advancements one year on
• What are the strengths of existing TIGIT axis targeted therapies that continue to drive development?
• What is the market opportunity versus unmet patient clinical need that TIGIT axis targeted approaches can address?
• How can we overcome the high bar set by standard of care?
• What does the landscape of emerging and/or competing therapeutic approaches look like in this space?
9:15 am
Deciphering the TIGIT Axis at a Mechanistic Level & Optimizing Preclinical Models
9:30 am Revealing How the CD155/TIGIT Axis Plays a Critical Role in Pancreatic Cancer Immune Evasion
Synopsis
• Novel preclinical models of neoantigen-expressing pancreas cancer uncover a key role for CD155/TIGIT
• CD155/TIGIT axis is sufficient to mediate immune evasion in PDAC
• TIGIT/PD-1 co-blockade plus CD40 agonism elicits robust anti-tumor activity in PDAC preclinical models
10:00 am Pan-Tumor TIGIT Expression Landscape in Real World Clinical Specimens
Synopsis
- TIGIT RNA expression measurements are highly sensitive and reproducible in FFPE solid tumor specimens
- TIGIT is significantly co-expressed with other immune checkpoint molecules
- TIGIT expression provides clinical insight into checkpoint inhibitor response in solid tumors
10:30 am Speed Networking Break
11:30 am Understanding the Complexity of CD226/TIGIT & CD96 for the Function of Tumor-Infiltrating T-Cells
Synopsis
• Exploring insights from single cell RNA sequencing in the head and neck cancer setting
• Deciphering the mechanistic reasons why TIGIT positive cells are not responding to TIGIT blockade
12:00 pm Uncovering that TIGIT KO NK Cells Have Enhanced Cytotoxicity Against Lung Cancer Cells
Synopsis
• Learning that TIGIT KO-NK cells kill tumor cells better as compared to WT NK cells
• Discussing the use of TIGIT KO NK cells as adoptive cell therapy alone or in combination with antibodies targeting TIGIT
12:30 pm Investigating New Combination Strategies Based on the Blockade of TIGIT to Increase Immune– Mediated Cytotoxicity in AML
Synopsis
• Evaluation of new targets for combination therapy with TIGIT to enhance T cell-mediated cytotoxicity in AML
• Dual checkpoint blockade for in vitro cytotoxicity assays
• Triple therapeutic approaches combining checkpoint blockade with metabolic targets for in vitro cytotoxicity assays
• Unleashing the innate immune system (including AML-associated macrophages and NK cells) by targeting TIGIT alone or in combination
• Repolarization and anti-leukemic phagocytosis of macrophages in vitro
• NK-cell mediated lysis of AML cells in vitr
13:00 pm Lunch
Afternoon Chairperson
2:00 pm Harnessing Spatial Approaches to Reveal TIGIT/PVR Axis & Improve Anti-PD1 Treatment in Gastrointestinal Cancer
Synopsis
• Using spatial analysis to identify the role of TIGIT/PVR within the tumor immune microenvironment
• Defining a combination strategy of TIGIT/PVR with PD-1/PD-L1 blockade
Leveraging Biomarkers to Identify Patient Responders, Monitor Treatment & Delve Deeper into TIGIT Axis Targeted Drug MoA
2:30 pm TIGIT: One Target with Multiple Ligands & Key Players
Synopsis
• Providing an up-to-date review of key potential biomarkers
• Designing smarter trials using relevant biomarkers
• Utilizing new technologies to harness the power of key biomarkers
3:00 pm Exploring TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin’s Lymphoma
Synopsis
• Demonstrating that TIGIT is induced on CAR-T cells after infusion into lymphoma patients
• Highlighting how TIGIT blockade can enhance the efficacy of CD19 CAR-T cells in animal models of human lymphoma
3:30 pm Afternoon Break
4:00 pm Sequential Single Cell Transcriptional & Protein Marker Profiling Reveals TIGIT as a Marker & Therapeutic Target to Enhance CD19 CAR-T Cell Therapy in Patients with Non-Hodgkin’s Lymphoma
Synopsis
• Exploring the role of TIGIT in CAR-T cells
• Investigating TIGIT and CD19 CAR-T cell combinatory therapy
4:30 pm Examining How Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells & Regulatory T-Cells to Improve PD-L1 Checkpoint Blockade
Synopsis
• Biomarker data from early phase studies including a randomized phase 2 study
• Preclinical confirmatory studies that shed light on the potential mechanisms of TIGIT blockade
5:00 pm TIGIT is Main Immune Checkpoint on Tumor-Antigen Specific T Cells in HPV-Positive Head & Neck Cancer
Synopsis
- Demonstration of a high throughput pipeline to detect tumor antigenspecific T-cells in patients
- Highlighting the importance of TIGIT as a target in HPV-positive head and
neck cancer
5:30 pm Chair’s Closing Remarks & Close of Day One
